Aktie A2DJNQ INITIATOR PHARMA A/S
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Initiator Pharma A/S

Aktien

A2DJNQ

DK0060775872

INIT

Markt geschlossen - Nasdaq Stockholm
Andere Börsenplätze
 12:17:31 30.04.2024 		% 5 Tage % 1. Jan.
8.92 SEK +0.22% Intraday Chart für Initiator Pharma A/S +2.06% -3.46%
23.02. Initiator Pharma A/S meldet Ergebnis für das vierte Quartal und das Gesamtjahr bis zum 31. Dezember 2023 CI
21.02. Initiator Pharma emittiert neue Aktien für die Umwandlung von Schulden MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Initiator Pharma's pudafensine preclinical pharmacology results published in the British Journal of Pharmacology
Initiator Pharma’s pudafensine preclinical pharmacology results published in the British Journal of Pharmacology
Initiator Pharma - Q4 2023 – Breathing optimism
INITIATOR PHARMA: YEAR END REPORT 2023
Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Initiator Pharma Issues New Shares for Debt Conversion
MAC Clinical Research converts its receivable into shares in Initiator Pharma
Initiator Pharma A/S - Issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021
Issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021
Initiator Pharma expands its position to a broader Sexual Health Franchise and intensifies its business development efforts
Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts
Initiator Pharma Q3 - A historical quarter
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Initiator Pharma reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensine
Initiator Pharma - Positive Phase IIb results
Initiator Pharma reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensine
Initiator Pharma reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensine
Initiator Pharma A/S Announces Positive Results from Phase IIb Clinical Trial with Pudafensine
Result of incentive program LTI2023 in Initiator Pharma
Initiator Pharma announces indication expansion, clinical drug candidates active in models of female sexual dysfunction
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2DJNQ Aktie
  4. Nachrichten Initiator Pharma A/S
  5. Andere Sprachen